JPRN-jRCT2080223881已完成3 期
Phase 3 Double-Blind Study to Compare the Efficacy and Safety of JTZ-951 with Darbepoetin Alfa in Anemic Patients with Chronic Kidney Disease Receiving Maintenance Hemodialysis <Switch / Maintenance Study>(SYMPHONY HD)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 173
研究概览
简要总结
SYMPHONY HD demonstrted that JTZ-951 was as effective as DA in maintaining Hb levels in anemic patients with CKD receiving maintenance hemodialysis, and was generally well-tolerated over 24 weeks
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Hemoglobin level of => 9.5 g/dL and < 12.0 g/d
排除标准
- •Patients with poorly controlled hypertension
- •Patients with congestive heart failure or unstable angina
- •Patients with malignancy
研究者
相似试验
已完成
3 期
Phase 3 Comparative Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis (SYMPHONY ND)Anemia with CKDJPRN-jRCT2080223814Japan Tobacco Inc.216
已完成
3 期
Phase 3 Study of JTZ-951 in ESA-naive Anemic Patients with Chronic Kidney Disease Receiving Hemodialysis (SYMPHONY HD-naive)anemia with CKDJPRN-jRCT2080223646Japan Tobacco Inc.34
已完成
2 期
An Early Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Receiving Maintenance Hemodialysis <Anemia Correction study>Anemia with CKDJPRN-jRCT2080222207Japan Tobacco Inc.40
已完成
2 期
ate Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Receiving Maintenance Hemodialysis <Anemia Correction / Maintenance Study>Anemia with CKDJPRN-jRCT2080222839Japan Tobacco Inc.71
已完成
2 期
ate Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis <Anemia Correction / Switch / Maintenance Study>Anemia with CKDJPRN-jRCT2080222829Japan Tobacco Inc.201